Form 4: Natera CEO Sells $9 Million in Stock Under Trading Plan

CEO Steven Chapman liquidated 41,124 shares of Natera common stock through a series of transactions on June 4, 2026.

Summary

• CEO and President Steven Chapman sold a total of 41,124 shares of common stock on June 4, 2026.
• The sales were executed in 14 separate tranches at weighted average prices ranging from $212.42 to $226.97 per share.
• Total gross proceeds from the transactions are approximately $9.1 million.
• Following these transactions, Chapman continues to hold 108,743 shares of Natera common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the transactions were pre-planned under a Rule 10b5-1 defense, although the size of the divestment is significant enough to warrant monitoring.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, which was originally adopted in December 2023 and amended most recently in March 2026.
• The reporting person retains a significant direct ownership stake of 108,743 shares, maintaining alignment with shareholder interests.

Negatives

• The sale of 41,124 shares represents a reduction of approximately 27% of the CEO's direct shareholding in a single day.
• Large-scale insider selling can sometimes be perceived by the market as a lack of confidence in near-term price appreciation.

Risks

• Potential for short-term downward pressure on the stock price due to the volume of shares sold in the open market.
• Market sensitivity to executive divestment, particularly if further sales are scheduled under the amended 10b5-1 plan.

Future Outlook

The use of a Rule 10b5-1 plan, especially one that has been amended multiple times, suggests that the executive has a structured approach to liquidity that may involve additional scheduled sales in future periods.

Industry Context

StockSavvy.ai notes that executives in high-growth genomic testing companies like Natera frequently utilize 10b5-1 plans to manage personal liquidity and portfolio diversification while navigating strict regulatory blackout periods.

Comparison to Industry Standards

• The sale volume is consistent with periodic liquidity events observed among senior leadership at peer diagnostic firms such as Exact Sciences and Guardant Health.
• Retention of over 100,000 shares remains within the standard range for established CEOs in the mid-to-large cap biotechnology sector.

Corporate Governance

Related Party Transactions

• The transactions involve the sale of company stock by the CEO to the open market.

Stakeholder Impact

• Shareholders may experience short-term price volatility due to the high volume of shares sold in a single day.
• The CEO remains incentivized through a remaining direct stake of 108,743 shares.

Next Steps

• Monitor future Form 4 filings to determine if the amended 10b5-1 plan dictates a recurring pattern of monthly or quarterly sales.

Key Dates

Recommendation

While the sale is substantial, it is programmatic and the CEO remains heavily invested in the company; investors should maintain current positions pending further fundamental business updates.

Keywords

Natera, NTRA, Insider Selling, Steven Chapman, Rule 10b5-1, CEO Stock Sale, Diagnostics, Biotechnology